Building on the success of the adoptive immunotherapy of cancer

以癌症过继免疫疗法的成功为基础

• 批准号: 8349144
• 负责人: Nicholas Restifo
• 金额: $ 138.01万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349144
• 关键词: Adoptive Immunotherapy; Advanced Malignant Neoplasm; Animal Model; Antigen Targeting; Autoantigens; Biotechnology; CD8B1 gene; Clinical Trials; Collaborations; Goals; Human; Immune response; Immunotherapy; Interleukin 2 Receptor Gamma; Malignant Neoplasms; Mediating; Memory; Molecular; Patients; Process; Research Personnel; Scientist; Shapes; Signal Transduction; T-Cell Activation; T-Lymphocyte; Testing; Translating; base; cytokine; design; in vitro Assay; neoplastic cell; programs; receptor; response; success; tumor

Adoptive immunotherapy for cancer: building on success Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are non-mutated self-antigens that are also expressed by tumor cells. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells.

癌症的免疫治疗：建立在成功的基础上在我们对T细胞介导的抗肿瘤应答的分子和细胞基础的理解方面已经取得了实质性的进展。T细胞是适应性抗肿瘤免疫应答的有效效应物。由肿瘤反应性CD8+ T细胞识别的一些靶抗原是也由肿瘤细胞表达的非突变的自身抗原。调节T细胞活化、功能和记忆的分子信号正在被阐明。来自共刺激分子的正信号和负信号都已显示出塑造抗肿瘤应答。细胞因子，包括那些具有含有共同的精氨酸受体γ链的受体的细胞因子，已显示改变效应CD8+ T细胞的编程。